D

Diffusion Pharmaceuticals Inc
NASDAQ:CRVO

Watchlist Manager
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Watchlist
Price: 7.98 USD -8.9% Market Closed
Market Cap: 65.9m USD
Have any thoughts about
Diffusion Pharmaceuticals Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-1.4
Current
0.4
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1.4
=
Enterprise Value
19.2m USD
/
EBITDA
-13.5m USD
All Countries
Close
EBITDA Growth
US
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Average EV/EBITDA: 17.3
Negative Multiple: -1.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 147.8 N/A
US
Abbvie Inc
NYSE:ABBV
15.6
29%
US
Amgen Inc
NASDAQ:AMGN
16.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
43%
US
Gilead Sciences Inc
NASDAQ:GILD
10
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.9 N/A
AU
CSL Ltd
ASX:CSL
20.4
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.6 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.2
2-Years Forward
EV/EBITDA
-0.5
3-Years Forward
EV/EBITDA
-0.3

See Also

Discover More